Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Ingiboyon May 03, 2023 2:13pm
116 Views
Post# 35428067

RE:RE:RE:On their MD&A that just came out

RE:RE:RE:On their MD&A that just came out Genie29J Quote:

"But as far as a partnership, Replicel has virtually no staff. So how would they partner together? What value would Replicel bring to the table? I personally believe Replicels plan all along is to simply sell RCH 01 rights outright and collect a huge payday."

The value that Replicel brings to a partnership is the rights to market RCH-O1 globally. Globally because they cancelled the contract with Shiseido which they had originally given them marketing rights for all of Asia. If Replicel wins or is about to win the Arbitration with Shiseido , Shiseido has no claim to the technology and if they wish to pursue this they have to make a deal with Replicel.  
Who knows what Shiseido is thinking at the moment.  Attempt to buy Replicel outright or form some sort of partnership.
I don't think that Andrew and Jamie are wanting to sell the company outright with all of the assets including the Dermal injector.  i think they see more money in their pockets with keeping control of the company and over time developing all of it's assets.

 
<< Previous
Bullboard Posts
Next >>